Tablas de Dosis Calculadora Mezclas & Stacks Aprender Blog Péptidos
Abrir Calculadora
Tablas de Dosis  ›  Lixisenatide
GLP-1 / Metabolic

Lixisenatide Guía & Tabla de Dosis

A short-acting GLP-1 agonist studied for postprandial glucose.

También conocido comoAdlyxin
Víasubcutaneous
Lixisenatide — Tabla de dosis
Cada fila citada
ObjetivoDosisFrecuenciaDuraciónEvidenciaFuente
Type 2 diabetes management (once-daily dosing) 10–20 mcg 1x/day per trial Clinical PMID 33068776 PMID 22945360
Neuroprotection / slowing motor disability progression in early Parkinson's disease 10–20 mcg 1x/day 12 months Clinical PMID 38598572
Solo para uso de investigación y educativo. No es consejo médico.

What is Lixisenatide?

Lixisenatide — also called Adlyxin — is a synthetic peptide that mimics a natural hormone in your gut called GLP-1 (glucagon-like peptide-1). Your body releases GLP-1 every time you eat. It tells the pancreas to release insulin, tells the liver to dial back sugar production, and even slows down how fast food leaves your stomach.

Lixisenatide is classified as a short-acting GLP-1 receptor agonist. That means it activates the same docking sites (receptors) as natural GLP-1, but it works for only a few hours rather than all day — making it especially useful for controlling blood sugar spikes right after meals.[1] Researchers have also begun exploring whether its effects on the brain might open up entirely new areas of study, including neurological conditions.[6]

Important note: Everything on this page describes research findings only. Lixisenatide is a research compound. Nothing here is medical advice.

How Lixisenatide Works

Think of GLP-1 receptors as small locks scattered across many organs — the pancreas, stomach, brain, and more. Lixisenatide is a key that fits those locks. When it binds, several things happen at once:

  • Insulin goes up — but only when blood sugar is already elevated, so the risk of dangerous low blood sugar is low.[4]
  • Glucagon goes down — glucagon is the hormone that tells your liver to dump sugar into the blood. Lixisenatide puts the brakes on it.[1]
  • The stomach slows down — food moves more slowly from the stomach into the intestine. This blunts the sharp sugar spike that normally follows a meal.[5] Because lixisenatide is short-acting, this gastric-slowing effect stays strong even with long-term use — unlike some longer-acting cousins in the same drug family.[1]
  • Appetite may decrease — signals reach the brain's appetite centers, which can reduce calorie intake.[2]

Researchers are also interested in GLP-1 receptors found in the brain itself. Activating those receptors appears to have protective effects on neurons in animal models, which is what sparked interest in conditions like Parkinson's disease.[6]

What the Research Shows

Blood Sugar Control in Type 2 Diabetes

Lixisenatide has been studied extensively as a once-daily injection for managing blood sugar in type 2 diabetes. Clinical trials showed it lowers after-meal glucose spikes effectively, and it can be used alone or combined with basal insulin.[1] Because it is short-acting, its strongest effect is on postprandial glucose — the surge that hits within an hour or two of eating — rather than overnight or fasting levels.[4] GLP-1 receptor agonists as a class are now recommended as a preferred early injectable therapy for type 2 diabetes, given their glucose-lowering power and low hypoglycemia risk.[1]

Weight and Metabolic Effects

Like other GLP-1 agonists, lixisenatide has been linked to modest reductions in body weight, largely because it slows gastric emptying and reduces appetite.[2] Weight loss tends to be smaller compared to longer-acting agents like semaglutide, but the metabolic benefits — including improvements in blood pressure and insulin sensitivity — are still an active area of research.[2]

Parkinson's Disease — A Surprising New Frontier

In 2024, a landmark phase 2 clinical trial called LIXIPARK put lixisenatide in the spotlight for an entirely different reason: Parkinson's disease. Researchers enrolled 156 people with early Parkinson's — diagnosed fewer than 3 years before the study — and randomly assigned them to daily lixisenatide injections or a placebo for 12 months, followed by a 2-month washout period.[3]

The key measure was motor disability, scored on a standardized scale called the MDS-UPDRS Part III (higher = worse). At 12 months, the lixisenatide group's scores barely changed (–0.04 points), while the placebo group worsened by about 3 points — a statistically significant difference (P = 0.007).[3] Crucially, after a 2-month break from the drug, the lixisenatide group still had better motor scores, hinting at a possible disease-modifying effect rather than just symptom masking.[3] The authors were careful to note that larger, longer trials are needed before any firm conclusions can be drawn.[3]

What Lixisenatide Is Being Studied For

  • Postprandial (after-meal) glucose management in type 2 diabetes[1]
  • Combination therapy with basal insulin for type 2 diabetes[1]
  • Weight and metabolic outcomes in obesity research[2]
  • Neuroprotection and slowing motor disability in early Parkinson's disease[3]
  • Broader neurodegeneration and GLP-1 brain-receptor biology[6]

How Lixisenatide Is Dosed in Research

Dosing in published trials has followed a titration approach — starting low to minimize nausea and stepping up as tolerated. For both the diabetes and Parkinson's research contexts, doses in the range studied are shown in the dosage chart on this page; use the interactive calculator to explore weight-based or protocol-based amounts. In the LIXIPARK Parkinson's trial, participants received once-daily subcutaneous injections for 12 months.[3] In diabetes trials, once-daily subcutaneous administration was also standard, with dose adjustments guided by tolerability.[1] Always refer to the specific study protocol for exact titration schedules.

Mixing and Storing Lixisenatide

In clinical and research settings, lixisenatide is supplied as a clear, colorless solution in a pre-filled pen device — it does not require reconstitution from powder. Research-grade material should be stored refrigerated (2–8 °C / 36–46 °F) and protected from light. Once in use, pens have typically been kept at room temperature (below 30 °C) for up to 14 days in clinical protocols. Never freeze lixisenatide — freezing destroys the peptide structure. Inspect the solution before each use; discard if it appears cloudy, discolored, or contains particles. Subcutaneous injection sites in trials have included the abdomen, thigh, or upper arm, rotating sites to minimize local reactions.

Sources

  1. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. — Molecular metabolism, 2021. PMID 33068776.
  2. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. — International journal of molecular sciences, 2023. PMID 37445623.
  3. Trial of Lixisenatide in Early Parkinson's Disease. — The New England journal of medicine, 2024. PMID 38598572.
  4. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. — Nature reviews. Endocrinology, 2012. PMID 22945360.
  5. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. — Advances in experimental medicine and biology, 2021. PMID 32077010.
  6. GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease. — International journal of molecular sciences, 2024. PMID 38612620.

Lixisenatide Preguntas

What is Lixisenatide?
Lixisenatide (brand name Adlyxin) is a synthetic short-acting GLP-1 receptor agonist — a peptide that mimics the gut hormone GLP-1. It activates GLP-1 receptors in the pancreas, stomach, and brain. It has been studied for blood sugar control in type 2 diabetes and, more recently, for potential neuroprotective effects in Parkinson's disease.[1][3] It is a research compound; this is not medical advice.
How does Lixisenatide work?
Lixisenatide binds to GLP-1 receptors and triggers a chain reaction: insulin secretion rises (only when blood sugar is high), glucagon is suppressed, and the stomach empties more slowly — blunting post-meal glucose spikes.[4] Because it is short-acting, it keeps its stomach-slowing effect even with long-term use, unlike longer-acting GLP-1 agents that lose this effect over time.[1]
What is Lixisenatide used for in research?
Researchers have studied lixisenatide primarily for postprandial glucose control in type 2 diabetes and as an add-on to basal insulin therapy.[1] It has also been investigated for weight and metabolic outcomes.[2] Most recently, a phase 2 trial found it significantly slowed motor disability progression in early Parkinson's disease over 12 months, sparking interest in its potential neuroprotective properties.[3]
How is Lixisenatide dosed in research studies?
Research trials have used once-daily subcutaneous injections, typically starting at a lower dose and titrating upward to reduce gastrointestinal side effects. The LIXIPARK Parkinson's trial ran daily injections for 12 months.[3] Diabetes trials also used once-daily dosing.[1] See the dosage chart on this page and the calculator for specific ranges used in published protocols.
How do you reconstitute Lixisenatide?
In clinical trials, lixisenatide was supplied as a ready-to-use solution in pre-filled pen injectors — no mixing or reconstitution required. Research-grade material should be stored refrigerated (2–8 °C), kept away from light, never frozen, and inspected for clarity before use. Once in use, pens in clinical protocols were typically kept at room temperature for up to 14 days.
Is Lixisenatide safe?
In clinical research, the most common side effects reported were gastrointestinal — nausea occurred in 46% and vomiting in 13% of participants in the LIXIPARK Parkinson's trial.[3] These effects are consistent with the GLP-1 class broadly.[1] Lixisenatide is a research compound and not approved for general use in all countries; all safety assessments should be conducted within the framework of a formal research protocol.